Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T13:42:16.933Z.
Calculation as of: 2026-10-06T13:42:16.933Z.
Quote observation: 2026-10-06T13:39:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$4.07M
EV/Sales Ratio
N/A
TTM Avg
0.35x
3Y Avg
5.55x
5Y Avg
4.43x
Market Cap
$3.42M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.38M
EV/Sales Ratio
N/A
TTM Avg
10.81x
3Y Avg
12.42x
5Y Avg
14.31x
Market Cap
$3.31M
EV/Sales Ratio
N/A
TTM Avg
46.50x
3Y Avg
481.93x
5Y Avg
1980.99x
Market Cap
$4.36M
EV/Sales Ratio
N/A
TTM Avg
66867.68x
3Y Avg
66867.68x
5Y Avg
66867.68x
Market Cap
$3.13M
EV/Sales Ratio
N/A
TTM Avg
126.62x
3Y Avg
132.74x
5Y Avg
132.74x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eocene Ltd. (EOCN) | $3.67M | N/A | N/A | N/A | N/A |
| Evogene Ltd. (EVGN)vs › | $3.53M | N/A | 1.52x | 2.03x | 233.77x |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.07M | N/A | 0.35x | 5.55x | 4.43x |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.42M | N/A | N/A | N/A | N/A |
| IceCure Medical Ltd (ICCM)vs › | $3.38M | N/A | 10.81x | 12.42x | 14.31x |
| Aethlon Medical, Inc. (AEMD)vs › | $3.31M | N/A | 46.50x | 481.93x | 1980.99x |
| GRI Bio, Inc. (GRI)vs › | $4.36M | N/A | 66867.68x | 66867.68x | 66867.68x |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.49M | 0.25x | 0.77x | 0.77x | 0.77x |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.13M | N/A | 126.62x | 132.74x | 132.74x |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.80M | N/A | 2126.93x | 1896.72x | 1896.72x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
